LeMaitre Vascular Posts Strong Q1 2026 Growth on Higher Pricing and Geographic Expansion
Event summary
- Q1 2026 sales reached $66.6 million, up 11% year-over-year (10% organic).
- Gross margin expanded by 350 basis points to 72.7%, driven by higher pricing and manufacturing efficiencies.
- Operating income surged 41% to $17.8 million, with EPS growing 42% to $0.68.
- Artegraft product line grew 36% worldwide, bolstered by international launch.
- Full-year guidance raised: 12% sales growth and 26% adjusted EPS growth expected.
The big picture
LeMaitre Vascular's Q1 2026 results highlight its ability to leverage higher pricing and geographic expansion to drive profitability. The company's strategic focus on manufacturing efficiencies and disciplined spending underscores its operational discipline in a competitive medical devices sector. With strong guidance for the full year, LeMaitre appears well-positioned to capitalize on global demand for vascular solutions.
What we're watching
- Pricing Power
- Whether LeMaitre can sustain higher ASPs amid potential competitive responses.
- Geographic Expansion
- The pace at which international markets, particularly EMEA and APAC, contribute to growth.
- Operational Leverage
- How effectively the company manages moderate operating expense growth while scaling.
Related topics